BSH 2017 | Combining venetoclax and obinutuzumab in the treatment of CLL
Martin Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK discusses the combination of venetoclax and obinutuzumab in the treatment of CLL at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. Novel CLL drugs have been shown to have significant activity individually, but recent research, such as the German CLL 14 study (NCT02242942) and a UK study (NCT01685892) have found that venetoclax in combination with obinutuzumab can be even more effective in combination, with the majority of patients achieving minimal residual disease negativity. This combination is successful because it works irrespective of specific genetic mutations and damage, such as p53, ATM mutations, and Notch1 mutations. The next problem to overcome with these novel treatments is their affordability and being able to introduce them into routine clinical practice in a timely manner. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
